{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Everolimus+5+MG",
    "query": {
      "intervention": "Everolimus 5 MG"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 138,
    "total_pages": 14,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Everolimus+5+MG&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T02:37:47.429Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00459186",
      "title": "The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic, Androgen Independent Prostate Cancer",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "RAD001",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 19,
      "start_date": "2005-11",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2016-05-16",
      "last_synced_at": "2026-11-19T02:37:47.429Z",
      "location_count": 5,
      "location_summary": "Boston, Massachusetts • Portland, Oregon",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00459186"
    },
    {
      "nct_id": "NCT01062399",
      "title": "Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors"
      ],
      "interventions": [
        {
          "name": "concurrent RAD001 10 mg/day",
          "type": "DRUG"
        },
        {
          "name": "concurrent temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "concurrent RAD001 2.5 mg/day",
          "type": "DRUG"
        },
        {
          "name": "concurrent RAD001 5 mg/day",
          "type": "DRUG"
        },
        {
          "name": "post-radiation RAD001 10 mg/day",
          "type": "DRUG"
        },
        {
          "name": "post-radiation temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Radiation Therapy Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 279,
      "start_date": "2010-12",
      "completion_date": "2022-05-20",
      "has_results": true,
      "last_update_posted_date": "2022-06-09",
      "last_synced_at": "2026-11-19T02:37:47.429Z",
      "location_count": 34,
      "location_summary": "Newark, Delaware • Gainesville, Florida • Jacksonville, Florida + 28 more",
      "locations": [
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01062399"
    },
    {
      "nct_id": "NCT01653847",
      "title": "Study in Recipients of Renal Transplant Allograft to Evaluate the Impact of Two Immunosuppressive Regimens",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "End Stage Renal Failure With Renal Transplant"
      ],
      "interventions": [
        {
          "name": "Tacrolimus with MMF",
          "type": "DRUG"
        },
        {
          "name": "Group 2: Tacrolimus with Everolimus.",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 88,
      "start_date": "2013-02",
      "completion_date": "2020-05",
      "has_results": true,
      "last_update_posted_date": "2021-03-02",
      "last_synced_at": "2026-11-19T02:37:47.429Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01653847"
    },
    {
      "nct_id": "NCT01150097",
      "title": "Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Liver Transplant Recipient"
      ],
      "interventions": [
        {
          "name": "Tacrolimus (reduced tacrolimus)",
          "type": "DRUG"
        },
        {
          "name": "Everolimus (reduced tacrolimus)",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus (tacrolimus elimination)",
          "type": "DRUG"
        },
        {
          "name": "Everolimus (tacrolimus elimination)",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus (tacrolimus control)",
          "type": "DRUG"
        },
        {
          "name": "Corticosteroids",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "20 Years to 75 Years"
      },
      "enrollment_count": 284,
      "start_date": "2010-03-31",
      "completion_date": "2013-05-03",
      "has_results": true,
      "last_update_posted_date": "2018-11-07",
      "last_synced_at": "2026-11-19T02:37:47.429Z",
      "location_count": 15,
      "location_summary": "Washington D.C., District of Columbia • Tampa, Florida • Lexington, Kentucky + 10 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01150097"
    },
    {
      "nct_id": "NCT01283334",
      "title": "A Study of Carboplatin, Cetuximab and RAD001 in Advanced Head and Neck Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Neoplasms",
        "Cancer of the Head and Neck"
      ],
      "interventions": [
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        },
        {
          "name": "RAD001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2011-01",
      "completion_date": "2014-11",
      "has_results": true,
      "last_update_posted_date": "2014-12-04",
      "last_synced_at": "2026-11-19T02:37:47.429Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01283334"
    },
    {
      "nct_id": "NCT01734512",
      "title": "PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pediatric Recurrent Progressive Low-grade Gliomas",
        "Pediatric Progressive Low-grade Gliomas"
      ],
      "interventions": [
        {
          "name": "Everolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "3 Years to 21 Years"
      },
      "enrollment_count": 65,
      "start_date": "2012-12-13",
      "completion_date": "2024-07-31",
      "has_results": true,
      "last_update_posted_date": "2025-09-09",
      "last_synced_at": "2026-11-19T02:37:47.429Z",
      "location_count": 18,
      "location_summary": "Los Angeles, California • Oakland, California • San Diego, California + 14 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01734512"
    },
    {
      "nct_id": "NCT00113360",
      "title": "RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neuroendocrine Carcinoma",
        "Islet Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "RAD001",
          "type": "DRUG"
        },
        {
          "name": "Octreotide Depot",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 67,
      "start_date": "2005-01",
      "completion_date": "2009-07",
      "has_results": true,
      "last_update_posted_date": "2026-07-06",
      "last_synced_at": "2026-11-19T02:37:47.429Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00113360"
    },
    {
      "nct_id": "NCT01088048",
      "title": "Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Indolent Non-Hodgkin's Lymphoma",
        "Chronic Lymphocytic Leukemia",
        "Mantle Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Idelalisib",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Bendamustine",
          "type": "DRUG"
        },
        {
          "name": "Ofatumumab",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Bortezomib",
          "type": "DRUG"
        },
        {
          "name": "Chlorambucil",
          "type": "DRUG"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 241,
      "start_date": "2010-03-25",
      "completion_date": "2015-04-28",
      "has_results": true,
      "last_update_posted_date": "2021-03-18",
      "last_synced_at": "2026-11-19T02:37:47.429Z",
      "location_count": 11,
      "location_summary": "Huntsville, Alabama • Los Angeles, California • Palo Alto, California + 8 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01088048"
    },
    {
      "nct_id": "NCT00622869",
      "title": "Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Liver Transplantation"
      ],
      "interventions": [
        {
          "name": "Tacrolimus (reduced tacrolimus)",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus (tacrolimus elimination)",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus (tacrolimus control)",
          "type": "DRUG"
        },
        {
          "name": "Everolimus (reduced tacrolimus)",
          "type": "DRUG"
        },
        {
          "name": "Everolimus (tacrolimus elimination)",
          "type": "DRUG"
        },
        {
          "name": "Corticosteroids",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 719,
      "start_date": "2008-01",
      "completion_date": "2012-04",
      "has_results": true,
      "last_update_posted_date": "2013-05-27",
      "last_synced_at": "2026-11-19T02:37:47.429Z",
      "location_count": 28,
      "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 20 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00622869"
    },
    {
      "nct_id": "NCT00363051",
      "title": "Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Islet Cell Carcinoma",
        "Neuroendocrine Carcinoma",
        "Neuroendocrine Tumor",
        "Pancreatic Neoplasms"
      ],
      "interventions": [
        {
          "name": "Everolimus 10 mg",
          "type": "DRUG"
        },
        {
          "name": "Octreotide Depot",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 160,
      "start_date": "2006-06",
      "completion_date": "2012-04",
      "has_results": true,
      "last_update_posted_date": "2013-05-10",
      "last_synced_at": "2026-11-19T02:37:47.429Z",
      "location_count": 20,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00363051"
    }
  ]
}